Showing 4801-4810 of 6808 results for "".
- Researcher Elaborates on Vitamin D Pretreatment to Enhance PDT for AKhttps://practicaldermatology.com/news/Researcher-Elaborates-Vitamin-D-Pretreatment-Enhance-PDT-AK/2475053/Vitamin D pretreatment can enhance photodynamic therapy (PDT) treatment of actinic keratoses (AK), and vitamin D receptor alleles correlate with serum vitamin D levels and squamous neoplasia, dermatology resident Taylor Bullock, MD, showed in a presentation at the Noah Worcester Dermatological So
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://practicaldermatology.com/news/prabotulinum-toxin-a-demonstrates-sustained-efficacy-at-day-180/2474898/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers publishing
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- Assessment Tool Combination Reveals Higher AD Risk and Atopic March Progressionhttps://practicaldermatology.com/news/assessment-tool-combination-reveals-higher-ad-risk-and-atopic-march-progression/2474810/Children with Staphylococcus aureus (SA) detected by metagenomic sequencing, as well as culture-based methods, had worse atopic dermatitis (AD) outcomes, new study results suggest. Des
- ElderDerm Co-Director Suggests Alternatives for 'Senile' in Diagnoseshttps://practicaldermatology.com/news/ElderDerm-Co-Director-Suggests-Alternatives-Senile-Diagnoses/2474689/The word senile can be avoided in discussing dermatologic diseases, Jaya Manjunath, MSIV, asserted at the ElderDerm 2025 Conference in Washington, DC. Manjunath, a medical student and co-director of the conference along with Practical Dermatology editorial board member Adam Friedm
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital